<DOC>
	<DOCNO>NCT00002696</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Randomized phase III trial compare cyclophosphamide , doxorubicin , fluorouracil cyclophosphamide , methotrexate , fluorouracil treat woman stage III breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Women With Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare response woman stage III breast cancer treat neoadjuvant fluorouracil , doxorubicin , cyclophosphamide ( FAC ) v cyclophosphamide , methotrexate , fluorouracil ( CMF ) . - Compare rate conservative surgical resectability locoregional control patient treat neoadjuvant therapy regimen . - Compare disease-free overall survival patient treat regimen . - Compare toxic effect regimens patient . - Compare compliance patient treat regimen . - Assess cosmetic result patient treat conservative surgery . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center . - Arm I : Patients receive fluorouracil ( 5-FU ) IV day 1 8 doxorubicin IV cyclophosphamide ( CTX ) IV day 1 ( FAC ) . Treatment continue every 3 week 3 course absence disease progression . - Arm II : Patients receive CTX IV , methotrexate IV , 5-FU IV day 1 8 ( CMF ) . Treatment continue every 4 week 3 course absence disease progression . Patients arm resectable disease third course chemotherapy undergo quadrantectomy axillary node dissection ( prefer ) modify radical mastectomy , follow 6 additional course chemotherapy arm randomize initially . Those patient without distant metastasis undergo locoregional radiotherapy begin concurrently initiation postoperative chemotherapy . Patients arm unresectable disease initial 3 course chemotherapy undergo locoregional radiotherapy surgical resection ( feasible ) . Quality life assess baseline monthly thereafter . Patients follow every 3-4 month 2 year , every 4-6 month 3 year , annually thereafter . PROJECTED ACCRUAL : Not specify</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III breast cancer Measurable disease No inflammatory breast cancer No synchronous bilateral breast cancer Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 21 75 Sex : Female Menopausal status : Not specify Performance status : ECOG 01 OR Zubrod 01 Life expectancy : More 12 week Hematopoietic : WBC great 4,000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 1.25 time upper limit normal ( ULN ) AST le 1.25 time ULN Renal : Creatinine clearance great 70 mL/min Cardiovascular : No angina pectoris No significant arrhythmia require therapy No bilateral bundle branch block No congestive heart failure No myocardial infarction Other : No medical psychiatric disease would preclude study therapy No malignancy except adequately treat nonmelanomatous skin cancer carcinoma situ cervix Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : No prior surgery except incisional biopsy fineneedle aspiration Other : No prior systemic therapy No concurrent caffeine alcohol</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>